Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
September 01 2021 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company
developing innovative therapeutics to treat life-threatening
diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief
Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
Chief Medical Officer of Aravive, will participate in a virtual
fireside chat at the H.C. Wainwright 23rd Annual Global Investment
Conference taking place September 13-15, 2021. The Company’s
presentation will be available for viewing on September 13, 2021 at
7:00 AM ET. Aravive will also participate in one-on-one meetings at
the conference.
This meeting is being held virtually, and a live webcast will be
accessible on the Events & Presentations
page of www.aravive.com. An archived replay of the
webcast will be available for 90 days following the webcast.
About AraviveAravive, Inc. is a
clinical-stage oncology company developing innovative therapeutics
to treat life-threatening diseases. Aravive’s lead therapeutic,
AVB-500, is a first-in-class ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway associated with tumor cell
growth, tumor metastasis, resistance to treatment and decreased
survival. AVB-500 has the potential to be combined with multiple
anticancer therapies across several tumor types, due to its novel
mechanism of action and favorable safety profile. AVB-500 has been
granted Fast Track Designation by the U.S. Food and Drug
Administration in platinum resistant recurrent ovarian cancer. The
Company is currently evaluating AVB-500 in a registrational Phase 3
trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in
second line plus, clear cell renal cell carcinoma, and a Phase 1b/2
trial in first-line treatment of pancreatic adenocarcinoma. The
Company is based in Houston, Texas and received a Product
Development Award from the Cancer Prevention & Research
Institute of Texas (CPRIT) in 2016. For more information, please
visit www.aravive.com.
Contact:Joseph T. SchepersVP, Investor
Relations, Aravive, Inc.jschepers@aravive.com (770) 558-5517
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024